These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Role of type I interferons and innate immunity in systemic sclerosis: unbalanced activities on distinct cell types? Barrat FJ; Lu TT Curr Opin Rheumatol; 2019 Nov; 31(6):569-575. PubMed ID: 31436583 [TBL] [Abstract][Full Text] [Related]
12. Anti-CXCL4 Antibody Reactivity Is Present in Systemic Sclerosis (SSc) and Correlates with the SSc Type I Interferon Signature. Lande R; Mennella A; Palazzo R; Pietraforte I; Stefanantoni K; Iannace N; Butera A; Boirivant M; Pica R; Conrad C; Chizzolini C; Riccieri V; Frasca L Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32707718 [TBL] [Abstract][Full Text] [Related]
13. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201 [TBL] [Abstract][Full Text] [Related]
14. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ponsoye M; Frantz C; Ruzehaji N; Nicco C; Elhai M; Ruiz B; Cauvet A; Pezet S; Brandely ML; Batteux F; Allanore Y; Avouac J Ann Rheum Dis; 2016 Dec; 75(12):2142-2149. PubMed ID: 26912566 [TBL] [Abstract][Full Text] [Related]
15. Combination of 5-aminolevulinic acid and iron prevents skin fibrosis in murine sclerodermatous graft-versus-host disease. Liu C; Yang X; Zhu P; Fujino M; Ito H; Takahashi K; Nakajima M; Tanaka T; Wang J; Zhuang J; Zou H; Li XK Exp Dermatol; 2018 Oct; 27(10):1104-1111. PubMed ID: 29978518 [TBL] [Abstract][Full Text] [Related]
16. A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Ruzek MC; Jha S; Ledbetter S; Richards SM; Garman RD Arthritis Rheum; 2004 Apr; 50(4):1319-31. PubMed ID: 15077316 [TBL] [Abstract][Full Text] [Related]
17. FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Huu DL; Matsushita T; Jin G; Hamaguchi Y; Hasegawa M; Takehara K; Fujimoto M Arthritis Rheum; 2013 Jun; 65(6):1624-35. PubMed ID: 23508350 [TBL] [Abstract][Full Text] [Related]
18. CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. Wenzel J; Lucas S; Zahn S; Mikus S; Metze D; Ständer S; von Stebut E; Hillen U; Bieber T; Tüting T J Am Acad Dermatol; 2008 Mar; 58(3):437-42. PubMed ID: 18280341 [TBL] [Abstract][Full Text] [Related]
19. Absence of cutaneous TNFalpha-producing CD4+ T cells and TNFalpha may allow for fibrosis rather than epithelial cytotoxicity in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. Askew D; Zhou L; Wu C; Chen G; Gilliam AC J Invest Dermatol; 2007 Aug; 127(8):1905-14. PubMed ID: 17429441 [TBL] [Abstract][Full Text] [Related]